Evidence map›Paper›PMID 23956436›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2013

Persistence of the bacterial pathogen Granulibacter bethesdensis in chronic granulomatous disease monocytes and macrophages lacking a functional NADPH oxidase.

Jessica Chu, Helen H Song, Kol A Zarember, Teresa A Mills, John I Gallin

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Febrile neutropenia management and outcomes in hematopoietic cell transplantation for chronic granulomatous disease.Transplant infectious disease : an official journal of the Transplantation Society · 2022
    Article
  2. International journal of molecular sciences · 2021
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. An AAVS1-targeted minigene platform for correction of iPSCs from all five types of chronic granulomatous disease.Molecular therapy : the journal of the American Society of Gene Therapy · 2015
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Jessica ChuLaboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Helen H Song
Kol A Zarember
Teresa A Mills
John I Gallin
National Institutes of Health · USNational Institute of Allergy and Infectious Diseases · US

Funding

Clinical Studies Of Abnormal Host DefenseZIAAI000155 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI GALLIN, JOHN I · 2009 to 2022
$3.1M
Laboratory Studies of Abnormal Host Defense and Immunoregulatory DiseasesZIAAI001151 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI ZAREMBER, KOL · 2011 to 2022
$2.4M
Effect Of Cytokines In Host Defense And InflammationZIAAI000521 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI GALLIN, JOHN I · 2009 to 2015
$1.1M
Intramural NIH HHS Z99 AI999999Intramural NIH HHS Z99 CL999999Intramural NIH HHS ZIA AI000155Intramural NIH HHS ZIA AI000521Intramural NIH HHS ZIA AI001151NIAID NIH HHS Y99 AI999999
6 · The paper itself

Abstract

Granulibacter bethesdensis is a Gram-negative pathogen in patients with chronic granulomatous disease (CGD), a deficiency in the phagocyte NADPH oxidase. Repeated isolation of genetically identical strains from the same patient over years, and prolonged waxing and waning seropositivity in some subjects, raises the possibility of long-term persistence. G. bethesdensis resists killing by serum, CGD polymorphonuclear leukocytes (PMN), and antimicrobial peptides, indicating resistance to nonoxidative killing mechanisms. Although G. bethesdensis extends the survival of PMN, persistent intracellular bacterial survival might rely on longer-lived macrophages and their precursor monocytes. Therefore, we examined phagocytic killing by primary human monocytes and monocyte-derived macrophages (MDM). Cells from both normal and CGD subjects internalized G. bethesdensis similarly. G. bethesdensis stimulated superoxide production in normal monocytes, but to a lesser degree than in normal PMN. Normal but not CGD monocytes and MDM killed G. bethesdensis and required in vitro treatment with IFN-γ to maintain this killing effect. Although in vitro IFN-γ did not enhance G. bethesdensis killing in CGD monocytes, it restricted growth in proportion to CGD PMN residual superoxide production, providing a potential method to identify patients responsive to IFN-γ therapy. In IFN-γ-treated CGD MDM, G. bethesdensis persisted for the duration of the study (7 d) without decreasing viability of the host cells. These results indicate that G. bethesdensis is highly resistant to oxygen-independent microbicides of myeloid cells, requires an intact NADPH oxidase for clearance, and can persist long-term in CGD mononuclear phagocytes, most likely relating to the persistence of this microorganism in infected CGD patients.

Indexed as

AcetobacteraceaeGram-Negative Bacterial InfectionsGranulomatous Disease, ChronicHumansMacrophagesMicroscopy, ConfocalMonocytesNADPH OxidasesNADPH Oxidases

Identifiers

PMID23956436
PMCPMC3769460
OpenAlexW2151383451

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.